文献速递肝病

长期给予促胰液素受体拮抗剂抑制Mdr2-/-小鼠胆道衰老和肝纤维化

Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2 -/- mice.
PubMed 文献 · Hepatology · 2023-02-20

在Mdr2-/-小鼠(原发性硬化性胆管炎模型)中,长期(3个月)给予促胰液素受体拮抗剂SCT 5-27可逆转胆道miR-125b和FoxA2表达下降,并减少胆管反应、胆道衰老、炎症、血管生成和纤维化。体外实验显示SCT 5-27通过上调miR-125b和FoxA2抑制人PSC胆管细胞增殖和衰老。结论认为调控SCT/SR轴可能对管理PSC至关重要。

要点

  • Mdr2-/-小鼠和晚期PSC患者胆道SCT/SR表达及血清SCT水平升高。
  • 长期SCT 5-27治疗逆转Mdr2-/-小鼠胆道miR-125b和FoxA2表达下降。
  • SCT 5-27通过上调FoxA2减少人PSC胆管细胞增殖和衰老。

核心结论

  • 调控SCT/SR轴可能对管理原发性硬化性胆管炎(PSC)至关重要。

研究设计与样本

  • 在雄性野生型和Mdr2-/-小鼠中给予生理盐水或SCT 5-27治疗3个月,并检测晚期PSC患者和健康对照的人体样本。
  • 体外使用人胆道PSC细胞系进行SCT 5-27处理及FoxA2下调和过表达实验。

主要发现

  • 与对照组相比,Mdr2-/-小鼠和晚期PSC患者胆道SCT/SR表达及血清SCT水平升高。
  • Mdr2-/-小鼠胆管反应、胆道衰老、肝脏炎症、血管生成、纤维化、胆道TGF-β1/VEGF-A轴表达以及蛋白激酶A和ERK1/2磷酸化显著增加。
  • Mdr2-/-小鼠胆道miR-125b和FoxA2表达较野生型小鼠下降,长期SCT 5-27治疗可逆转该变化。
  • 体外SCT 5-27处理人PSC细胞系降低增殖和衰老及SR/TGF-β1/VEGF-A轴,增加miR-125b和FoxA2表达。
  • 下调FoxA2阻止SCT 5-27诱导的胆道损伤减少,而过表达FoxA2降低人PSC细胞系增殖和衰老。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Secretin (SCT) and secretin receptor (SR, only expressed on cholangiocytes within the liver) play key roles in modulating liver phenotypes. Forkhead box A2 (FoxA2) is required for normal bile duct homeostasis by preventing the excess of cholangiocyte proliferation. Short-term administration of the SR antagonist (SCT 5-27) decreased ductular reaction and liver fibrosis in bile duct ligated and Mdr2 -/- [primary sclerosing cholangitis (PSC), model] mice. We aimed to evaluate the effectiveness and risks of long-term SCT 5-27 treatment in Mdr2 -/- mice. APPROACH AND RESULTS: In vivo studies were performed in male wild-type and Mdr2 -/- mice treated with saline or SCT 5-27 for 3 months and human samples from late-stage PSC patients and healthy controls. Compared with controls, biliary SCT/SR expression and SCT serum levels increased in Mdr2 -/- mice and late-stage PSC patients. There was a significant increase in ductular reaction, biliary senescence, liver inflammation, angiogenesis, fibrosis, biliary expression of TGF-β1/VEGF-A axis, and biliary phosphorylation of protein kinase A and ERK1/2 in Mdr2 -/- mice. The biliary expression of miR-125b and FoxA2 decreased in Mdr2 -/- compared with wild-type mice, which was reversed by long-term SCT 5-27 treatment. In vitro , SCT 5-27 treatment of a human biliary PSC cell line decreased proliferation and senescence and SR/TGF-β1/VEGF-A axis but increased the expression of miR-125b and FoxA2. Downregulation of FoxA2 prevented SCT 5-27-induced reduction in biliary damage, whereas overexpression of FoxA2 reduced proliferation and senescence in the human PSC cell line. CONCLUSIONS: Modulating the SCT/SR axis may be critical for managing PSC.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wu N, Zhou T, Carpino G, et al. Prolonged administration of a secretin receptor antagonist inhibits biliary senescence and liver fibrosis in Mdr2 -/- mice. Hepatology. 2023. PMID: 36799446. doi:10.1097/HEP.0000000000000310

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。